Could not connect to DB: 1040: Too many connectionsCould not execute 'UPDATE pressrelease SET r_hits = r_hits+ 1, r_total_hits = r_total_hits+ 1, r_pub_hits = r_pub_hits+ 1, r_total_pub_hits = r_total_pub_hits+ 1 WHERE r_id = 147001' on database eurekalert:
2002: Can't connect to local MySQL server through socket '/tmp/mysql.sock' (2) [ Back to EurekAlert! ] Public release date: 21-Oct-2009
[ | E-mail Share Share ]

Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-632-5357
Dana-Farber Cancer Institute

Researchers exploit genetic 'co-dependence' to kill treatment-resistant tumor cells

BOSTON and CAMBRIDGE--Cancer cells fueled by the mutant KRAS oncogene, which makes them notoriously difficult to treat, can be killed by blocking a more vulnerable genetic partner of KRAS, report scientists at the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT.

The laboratory results, published by Nature on its Web site as an advanced online publication and later in a print edition, demonstrate a potential advance against many major tumors which, because they harbor the mutant KRAS cancer gene, are highly aggressive and respond poorly to treatment. By targeting the second, more easily inhibited "co-dependent" gene, TBK, the strategy bypasses the so far unfruitful head-on assault against the highly resistant KRAS gene.

"These results represent a new way of targeting oncogenes that have been refractory to standard treatments," said William Hahn, MD, PhD, senior author of the report, of Dana-Farber, the Broad Institute, and Harvard Medical School (HMS). "What's particularly exciting is that this approach is potentially highly specific to cancer cells, and therefore should have little toxicity to normal tissues."

The first author is David Barbie, MD, of the two institutes and HMS.

The mutant KRAS oncogene acts like a broken switch, allowing runaway cell growth in nearly all pancreatic tumors, about 25 percent of colorectal, and 25 to 30 percent of lung cancers. When physicians detect KRAS mutations in a cancer, it usually predicts the patient won't respond well to standard therapies. "If you have a mutant KRAS, we can't use many of our newest drugs," noted Hahn.

For many years, researchers were hopeful that drugs could be designed to shut down KRAS, but this has proven virtually impossible. However, its co-dependent partner, TBK1, encodes a protein kinase -- a type of molecular switch for which many inhibitors already exist. TBK1 is not a cancer-causing gene, but in KRAS-driven tumors, TBK1 activity enables cancer cells to survive that otherwise would be destroyed by the body because they are abnormal and dangerous.

TBK1 is the second such gene co-dependent with KRAS to be discovered: In May, a team that included Barbie, Hahn, and other researchers reported in Cell that a kinase gene, STK33, had a similar function in KRAS tumors. Senior author of that report was D. Gary Gilliland, MD, PhD of Brigham and Women's Hospital, Dana-Farber, the Broad, and HMS.

The new approach exploits a relationship between the KRAS and TBK1 genes known as "synthetic lethality." The term refers to a partnership in which two genes (usually mutated) in a cell have a combined effect that neither has by itself. In some cases, neither mutation alone will kill a cell but the presence of both is lethal.

In the case of KRAS tumors, the opposite is true: both KRAS and TBK1 must be active for the cancer cell to survive; suppressing one or the other kills the cell.

The key role of TBK1 was identified in a large-scale search using the combined resources of Dana-Farber and the Broad Institute to hunt for genes that were essential exclusively to cells with mutant KRAS, but not to cells with wild-type (non-mutant) KRAS or other normal cells.

Working with scientists in the Broad's RNAi Platform, the team used RNA interference (RNAi) methods to turn off thousands of different genes in 20 laboratory cancer and non-cancer cells. They then sought out genes that, when shut down by short pieces of RNA strands, caused KRAS cells to self-destruct, but had no effect on normal cells. The screening process first identified 45 potential candidates, which were further winnowed in a secondary screen to single out TBK1.

"Until four or five years ago, you couldn't have contemplated doing an experiment like this on so large a scale," noted Hahn. "We now have the tools that make this possible." The new paper and its predecessor "really make it clear that you can do this in human cells."

The discoveries of TBK1 and STK33 are only the first of what the scientists expect will be many more "co-dependent" genes in cancer cells that may prove valuable as drug targets.

"We plan to screen 300 cell lines over the next couple of years," said Hahn. "The aim is to create a dataset in which any investigator can say, 'I'm looking for genes that interact with this oncogene or that tumor-suppressor gene.' Our intent is to make these data public in order to help move the field forward."

In the meantime, Hahn said there is considerable interest in testing existing kinase inhibitors as potential new therapies for KRAS tumors. He added that researchers at Dana-Farber and the Broad are interested in developing novel molecular tools to suppress the action of co-dependent oncogene partners.

###

The research was supported by grants from the National Cancer Institute and a variety of foundations and organizations.

About Dana-Farber Cancer Institute

Dana-Farber Cancer Institute (www.dana-farber.org) is a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States. It is a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC), designated a comprehensive cancer center by the National Cancer Institute. It is the top ranked cancer center in New England, according to U.S. News & World Report, and one of the largest recipients among independent hospitals of National Cancer Institute and National Institutes of Health grant funding.

About the Broad Institute of MIT and Harvard

The Eli and Edythe L. Broad Institute of MIT and Harvard was founded in 2003 to empower this generation of creative scientists to transform medicine with new genome-based knowledge. The Broad Institute seeks to describe all the molecular components of life and their connections; discover the molecular basis of major human diseases; develop effective new approaches to diagnostics and therapeutics; and disseminate discoveries, tools, methods and data openly to the entire scientific community.

Founded by MIT, Harvard and its affiliated hospitals, and the visionary Los Angeles philanthropists Eli and Edythe L. Broad, the Broad Institute includes faculty, professional staff and students from throughout the MIT and Harvard biomedical research communities and beyond, with collaborations spanning over a hundred private and public institutions in more than 40 countries worldwide. For further information about the Broad Institute, go to www.broadinstitute.org.



[ Back to EurekAlert! ] [ | E-mail Share Share ]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.